Second-line treatment for warm autoimmune anemia
Treatments studied
Part of Blood & lymphatic, Immune system & allergy clinical trials.
This Phase 3 study tests a second-line treatment for adults with warm autoimmune hemolytic anemia whose disease is not controlled with steroids, who cannot tolerate steroids, or who decline standard treatment. It aims to improve anemia and reduce ongoing red blood cell destruction caused by the immune system.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be age 19 or older and have warm autoimmune hemolytic anemia confirmed by blood tests plus a positive direct antiglobulin test
- Your anemia is not improving with steroid treatment, you cannot tolerate steroids, or you chose not to use standard treatment
- Have no known “secondary cause” of the anemia (no underlying condition that caused it)
- Have no history or signs of lymphoma or other lymph-type cancers
- You cannot be pregnant or breastfeeding
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new treatment using a patient's own immune cells that are modified to find and attack specific targets (CD19 and BCMA) on faulty B cells. It is designed for adults with autoimmune hemolytic anemia (AIHA) that has not improved after at least 3 standard treatments.
This trial tests a new CAR-T cell therapy that targets two proteins (CD19 and BCMA) on immune cells to treat warm antibody autoimmune hemolytic anemia that has not responded to standard treatments. The goal is to see if it is safe and can help control the disease.
This trial studies sirolimus in adults with “warm” autoimmune hemolytic anemia (or Evans syndrome) when steroids have not worked or the anemia has returned. It may help control the immune attack on red blood cells, but there are specific safety checks for liver health and infections.
This trial tests a new cell therapy called YTS109 for people with autoimmune hemolytic anemia (AIHA) that hasn't improved with standard treatments. The goal is to see if this therapy can help control the disease when other options have failed.
This study tests whether adding a medication called sirolimus to steroid treatment works better than steroids alone for newly diagnosed autoimmune hemolytic anemia (a condition where your body attacks its own red blood cells). You'll be randomly assigned to one treatment group, and researchers will track how well each approach helps your body recover.
This trial tests an experimental cell therapy called YTS109 for people with autoimmune hemolytic anemia (AIHA) that hasn't improved after at least three prior treatments. It aims to see if the therapy can help control the disease and improve anemia symptoms.
Hear when a new Primary Autoimmune Hemolytic Anemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.